SVNanoVax SIGNED
Structural Vaccinology in the design of bionanoparticles with multi-copy antigen display for vaccines with enhanced efficacy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SVNanoVax project word cloud
Explore the words cloud of the SVNanoVax project. It provides you a very rough idea of what is the project "SVNanoVax" about.
Project "SVNanoVax" data sheet
The following table provides information about the project.
| Coordinator |
GLAXOSMITHKLINE VACCINES SRL
Organization address contact info |
| Coordinator Country | Italy [IT] |
| Total cost | 168˙277 € |
| EC max contribution | 168˙277 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2014 |
| Funding Scheme | MSCA-IF-EF-RI |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-06-15 to 2017-06-14 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | GLAXOSMITHKLINE VACCINES SRL | IT (SIENA) | coordinator | 168˙277.00 |
Map
Project objective
Vaccines are the most effective way to protect humans from infectious disease and may save over 2 million lives per year (Delany, 2013). A key issue for future vaccines is how to improve immunogenicity without reducing safety (Bachmann, 2010). Another challenge is that high antigen sequence variability enables pathogens to escape the host response. To overcome these challenges, this proposal combines Structural Vaccinology and bionanoparticle (BNP) design, to generate novel self-assembling BNPs with multi-copy antigen display for the development of safe vaccine antigens with enhanced immunogenicity and breadth of coverage.
We will generate antigen-BNPs for a 2nd generation vaccine against Neisseria meningitidis serogroup B (MenB), a major cause of sepsis and invasive disease (Pace, 2012). This research may also potentiate antigen-BNP technology suitable for other vaccines. Firstly, we will use functional (bactericidal) monoclonal antibodies to map the most protective epitopes on the 3D structures of two key MenB antigens, fHbp and NadA, which contribute strongly to our recently-approved 1st generation MenB vaccine, Bexsero (O’Ryan, 2014). To aid this, we have developed wide expertise in structure-focused epitope mapping (Malito, 2013). Secondly, we will design optimized antigens stably displaying the best epitopes, an approach that we have pioneered and termed ‘Structural Vaccinology’ (Scarselli, 2011). Finally, self-assembling protein bionanoparticles displaying ordered arrays of the optimized antigens will be prepared, in order to generate novel highly-immunogenic, broadly-protective MenB vaccine candidates.
The proposal offers an exciting career development opportunity encompassing novel high-quality research to combine and deliver the promises of Structural Vaccinology and nanobiology, with a high probability of success to generate innovative new vaccine antigens for products to protect humans against meningococcal and other infectious diseases.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2016 |
Jacinto López-Sagaseta, Enrico Malito, Rino Rappuoli, Matthew J. Bottomley Self-assembling protein nanoparticles in the design of vaccines published pages: 58-68, ISSN: 2001-0370, DOI: 10.1016/j.csbj.2015.11.001 |
Computational and Structural Biotechnology Journal 14 | 2019-06-18 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SVNANOVAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SVNANOVAX" are provided by the European Opendata Portal: CORDIS opendata.